Top

CNS Drugs

Published in:

01-08-2014 | Original Research Article

Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions

Authors: Hajo M. Hamer, Karel Kostev

Published in: CNS Drugs | Issue 8/2014

Abstract

Background

Large epidemiological databases facilitate the study of medical care in different subgroups of the population and how such care compares with standard treatment guidelines. This study aimed for such analyses regarding utilization of antiepileptic drugs (AEDs) for epilepsy in Germany.

Method

The data source was the Disease Analyzer^® database that is representative for the German population and assembles anonymous demographic and medical (diagnoses, prescriptions) data obtained from the practice computer system of general practitioners and specialists throughout Germany. A total of 43,712 adult patients with an epilepsy diagnosis (International Classification of Diseases, 10th edition [ICD10] code: G40.X) seen in 2010–2012 by 346 neurologists were retrospectively analysed according to sociodemographic characteristics, comorbidity, and AED treatment. Multivariate logistic regression was applied to calculate adjusted odds ratios (ORs) with 95 % confidence intervals (CIs).

Results

As compared with women, men were less likely to receive lamotrigine (OR 0.68; 95 % CI 0.65–0.72; p < 0.001) and were treated preferably with carbamazepine (OR 1.29; 95 % CI 1.23–1.35; p < 0.001). As compared with patients covered by private health insurance (PHI), patients with statutory health insurance (SHI) were treated more often with valproate (OR 1.19; 95 % CI 1.07–1.31; p < 0.001) and showed a higher rate of obesity (SHI: 3.1 %; PHI: 1.6 %; p < 0.001), while PHI was associated with administration of levetiracetam (OR 1.27; 95 % CI 1.16–1.4; p < 0.001). Carbamazepine (OR 1.25; 95 % CI 1.17–1.31; p < 0.001) and primidone (OR 1.23; 95 % CI 1.08–1.38; p < 0.001) were administered to a larger extent in rural versus urban areas. Lamotrigine (OR 1.31; 95 % CI 1.23–1.39; p < 0.001) was used more often in West than in East Germany. Living in an urban community raised the likelihood of being treated with levetiracetam (OR 1.23; 95 % CI 1.17–1.28; p < 0.001).

Conclusions

In spite of common guidelines, AED treatment differed significantly among adults with epilepsy in Germany. Besides gender, type of health insurance and place of residence strongly influenced AED administration.

Hamer HM, Dodel R, Strzelczyk A, Balzer-Geldsetzer M, Reese JP, Schoffski O, et al. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany—a nationwide population-based study in children and adults. J Neurol. 2012;259(11):2376–84.PubMedCrossRef

Strzelczyk A, Haag A, Reese JP, Nickolay T, Oertel WH, Dodel R, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav. 2013;27(3):433–8.PubMedCrossRef

Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47(10):617–26.PubMedCrossRef

Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15.PubMedCentralPubMedCrossRef

Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bul World Health Organ. 2010;88(4):260–6.CrossRef

Huber J, Mielck A. Morbidity and healthcare differences between insured in the statutory (“GKV”) and private health insurance (“PKV”) in Germany. Review of empirical studies. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010;53(9):925–38.PubMedCrossRef

Odeyemi IA, Nixon J. The role and uptake of private health insurance in different health care systems: are there lessons for developing countries? Clinicoecon Outcomes Res. 2013;5:109–18.PubMedCentralPubMedCrossRef

Mattsson P, Tomson T, Eriksson O, Brannstrom L, Weitoft GR. Sociodemographic differences in antiepileptic drug prescriptions to adult epilepsy patients. Neurology. 2010;74(4):295–301.PubMedCrossRef

Meyer AC, Dua T, Boscardin WJ, Escarce JJ, Saxena S, Birbeck GL. Critical determinants of the epilepsy treatment gap: a cross-national analysis in resource-limited settings. Epilepsia. 2012;53(12):2178–85.PubMedCrossRef

10.

Malmgren K, Flink R, Guekht AB, Michelucci R, Neville B, Pedersen B, et al. ILAE Commission of European Affairs Subcommission on European Guidelines 1998–2001: the provision of epilepsy care across Europe. Epilepsia. 2003;44(5):727–31.PubMedCrossRef

11.

Begley CE, Basu R, Reynolds T, Lairson DR, Dubinsky S, Newmark M, et al. Sociodemographic disparities in epilepsy care: results from the Houston/New York City health care use and outcomes study. Epilepsia. 2009;50(5):1040–50.PubMedCrossRef

12.

Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):133–41.PubMedCentralPubMedCrossRef

13.

Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ. 2012;344:e281.PubMedCrossRef

14.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17.PubMedCrossRef

15.

Holden EW, Grossman E, Nguyen HT, Gunter MJ, Grebosky B, Von Worley A, et al. Developing a computer algorithm to identify epilepsy cases in managed care organizations. Dis Manag. 2005;8(1):1–14.PubMedCrossRef

16.

Schnusenberg O, Loh CP, Nihalani K. The role of financial wellbeing, sociopolitical attitude, self-interest, and lifestyle in one’s attitude toward social health insurance. Appl Health Econ Health Policy. 2013;11(4):369–81.PubMedCrossRef

Title: Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions
Authors: Hajo M. Hamer
Karel Kostev
Publication date: 01-08-2014
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 8/2014
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.1007/s40263-014-0187-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions

Abstract

Background

Method

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2014

Diclofenac Potassium Powder for Oral Solution: A Review of Its Use in Patients with Acute Migraine

Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?

Sodium Oxybate in the Treatment of Alcohol Withdrawal Syndrome: A Randomized Double-Blind Comparative Study versus Oxazepam. The GATE 1 Trial

Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis

Osteoporosis and Multiple Sclerosis: Risk Factors, Pathophysiology, and Therapeutic Interventions

Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence